Clinical Trial Update: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial of sacituzumab govitecan in primary HER2-negative breast cancer (including triple-negative breast cancer) is currently active but not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: HER2-negative Breast Cancer, Triple Negative Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING